MetaVia's DA-1726 Shows Promising Results in Obesity Treatment with Significant Weight Loss

MetaVia Achieves Breakthrough Results in Obesity Treatment with DA-1726

MetaVia Inc. announces significant advancements in the treatment of obesity through its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog. This innovative therapy targets cardiometabolic diseases, a growing health concern worldwide. The trial's results, particularly from the non-titrated 48 mg cohort, reveal that patients experience an average weight loss of 9.1%, equating to 21.2 lbs, by Day 54. In addition to weight reduction, participants show a statistically significant decrease in waist circumference, with a reduction of 9.8 cm (3.8 inches), highlighting the therapy's potential effectiveness in addressing visceral fat, a key risk factor for metabolic complications.

The data collected during the trial also demonstrates notable improvements in metabolic health, with participants reporting a reduction in fasted glucose levels by 12.3 mg/dL from a baseline of 105.3 mg/dL. Furthermore, liver stiffness decreases by 23.7%, suggesting that DA-1726 not only aids in weight management but also offers direct benefits for liver health. These promising outcomes indicate that DA-1726 could serve as a groundbreaking option compared to existing treatments, especially as it appears to outperform GLP-1 agonists in addressing visceral fat loss, as noted by Hyung Heon Kim, president and CEO of MetaVia.

Despite mild to moderate gastrointestinal events reported by participants, the trial maintains a strong safety profile, with no treatment-related discontinuations. By Day 26 of the trial, results already show a 6.1% weight loss (14.6 lbs) and a 5.8 cm (2.3 inches) reduction in waist circumference. The extended eight-week period of the trial provides a comprehensive view of DA-1726's efficacy and tolerability, positioning it as a potential best-in-class therapy for obesity and related metabolic disorders.

In addition to the promising clinical results, MetaVia's commitment to addressing cardiometabolic diseases underscores the company's strategic focus in a rapidly evolving biotechnology landscape. As the prevalence of obesity and its associated health risks rise globally, therapies like DA-1726 offer hope for effective interventions that could redefine treatment paradigms.

Moving forward, MetaVia aims to build on these findings, exploring further phases of clinical development for DA-1726 while continuing to innovate within the cardiometabolic space. The company's ability to advance therapies that not only promote weight loss but also improve overall metabolic health positions MetaVia as a key player in the biotechnology industry addressing pressing health challenges.